Not provided
Not provided
Not provided
Not provided
Not provided
At the request of the study site, this study has been closed and access to study-related data is unavailable. We are unable to submit the results-data.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Shriners Hospitals for Children | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine the safety and efficacy of administration of propranolol for reducing heart rate and blood pressure in burn injury.
Other purposes of this study are to study the effect on muscle function, the infectious process, sepsis, systemic inflammation and long-term scarring. Quality of life will also be looked at over time.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Propranolol | Active Comparator | Propranolol by mouth given daily throughout hospitalization for up to 12 months |
|
| Sugar Pill | Placebo Comparator | Placebo by mouth given daily throughout hospitalization for up to 12 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Propranolol | Drug | Propranolol by mouth given daily throughout hospitalization for up to 12 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Resting heart rate multiplied by the systolic blood pressure measurement= rate pressure product | Multiply the subjects resting heart rate and systolic blood pressure measurements and average every 24 hours while hospitalized (an average of 4 weeks) | Measured during acute hospital stay, an average of 4 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of deaths | Number of deaths will be compared between placebo group and propranolol treatment groups. | time of randomization up to one year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David N Herndon, MD | University of Texas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Shriners Hospitals for Children | Sacramento | California | 95817 | United States | ||
| Shriners Hospitals for Children |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 15, 2023 | |
| Reset | Jul 5, 2023 | |
| Release | Mar 27, 2026 | |
| Reset | Apr 16, 2026 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 15, 2023 | Jul 5, 2023 | |||
| Mar 27, 2026 |
| ID | Term |
|---|---|
| D002056 | Burns |
| ID | Term |
|---|---|
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D011433 | Propranolol |
| D008790 | Metoprolol |
| ID | Term |
|---|---|
| D050198 | Phenoxypropanolamines |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo by mouth given daily throughout hospitalization for up to 12 months. |
|
|
| Boston |
| Massachusetts |
| 02114 |
| United States |
| Shriners Hospitals for Children | Cincinnati | Ohio | 45229 | United States |
| Shriners Hospitals for Children | Galveston | Texas | 77551 | United States |
| Apr 16, 2026 |
| D009930 |
| Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D011083 | Polycyclic Compounds |